An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: MK0954, losartan potassium / Duration of Treatment - 12 weeks (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.
Clinical Details
Official title: An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension
Study design: Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment
Primary outcome: Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at
least 4 weeks prior to visit 1
- Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure
between 90 to 99mmhg taken at visit 1
Exclusion Criteria:
- History of angina pectoris that has not been stabilized in the past 6 weeks
- History of clinically significant abnormal lab results or diseases
- Myocardial infarction within the past 6 months
- Stroke in the past 6 months
Locations and Contacts
Additional Information
Starting date: January 2007
Last updated: March 16, 2007
|
